Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-818 in moderate-to-severe atopic dermatitis
CTR20253869Phase 2Active
- Sponsor
- Heji Pharma
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of soquelitinib in atopic dermatitis (AD), sponsored by Heji Pharma. Started Jan 2026; status: active.
02
Drugs
soquelitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20253869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253869.